Scientists believe the illegal drug MDMA, also known as ecstasy, has an untapped potential to treat post-traumatic stress disorder (PTSD). But they say plans to test the drug on war veterans in [...]
This presentation was delivered by PRISM Vice-President Dr Stephen Bright at a fundraising seminar and dinner held at The Melbourne Brain Centre, Parkville on 8th April 2016.
This presentation was delivered by PRISM President Dr Martin Williams at a fundraising seminar and dinner held at The Melbourne Brain Centre, Parkville on 8th April 2016.
Dr Stephen Bright talks to The Psychedelia Podcast about the problems facing the psychedelic movement in Australia
Dr Stephen Bright, a Psychologist working at Curtin University discusses psychedelic therapy.
Dr Martin Williams, president of Psychedelic Research in Science & Medicine talks on ABC Radio Alice Springs
MDMA — more commonly known as ecstasy — is one step closer to becoming a legal form of treatment for post-traumatic stress disorder (PTSD) in the United States.
In September 2016 PRISM’s Vice President Dr Stephen Bright spoke at Beyond Psychedelics, a global multidisciplinary psychedelic forum held in Prague, Czech Republic.
A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research
When Martin Williams’ research plan was first rejected by an ethics committee in 2012, he understood why. The medicinal chemistry researcher could see some valid sticking points.
Click here to listen: https://soundcloud.com/enpsychedelia/the-psychedelic-inquirer-prism-interview
Some drugs that have therapeutic benefits are banned because of emerging patterns of use that do not conform to dominant paradigms. Such policies are often driven by morality rather than evidence.
As UK researchers begin human therapeutic experiments using the psychedelic drug LSD an Australian group are setting up the nation’s first clinical study using MDMA